Literature DB >> 25724395

Generation of insulin-producing cells from C3H10T1/2 mesenchymal progenitor cells.

Ruo-Lei Jian1, Li-Bin Mao1, Yao Xu1, Xiao-Fan Li1, Feng-Po Wang1, Xue-Gang Luo1, Hao Zhou1, Hong-Peng He1, Nan Wang2, Tong-Cun Zhang3.   

Abstract

Mesenchymal stem cells (MSCs) have been reported to be an attractive source for the generation of transplantable surrogate β cells. A murine embryonic mesenchymal progenitor cell line C3H10T1/2 has been recognized as a model for MSCs, because of its multi-lineage differentiation potential. The purpose of this study was to explore whether C3H/10T1/2 cells have the potential to differentiate into insulin-producing cells (IPCs). Here, we investigated and compared the in vitro differentiation of rat MSCs and C3H10T1/2 cells into IPCs. After the cells underwent IPC differentiation, the expression of differentiation markers were detected by immunocytochemistry, reverse transcription-polymerase chain reaction (RT-PCR), quantitative real-time RT-PCR (qRT-PCR) and Western blotting. The insulin secretion was evaluated by enzyme-linked immunosorbent assay (ELISA). Furthermore, these differentiated cells were transplanted into streptozotocin-induced diabetic mice and their biological functions were tested in vivo. This study reports a 2-stage method to generate IPCs from C3H10T1/2 cells. Under specific induction conditions for 7-8 days, C3H10T1/2 cells formed three-dimensional spheroid bodies (SBs) and secreted insulin, while generation of IPCs derived from rat MSCs required a long time (more than 2 weeks). Furthermore, these IPCs derived from C3H10T1/2 cells were injected into diabetic mice and improves basal glucose, body weight and exhibited normal glucose tolerance test. The present study provided a simple and faithful in vitro model for further investigating the mechanism underlying IPC differentiation of MSCs and cell replacement therapy for diabetes.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C3H10T1/2 cells; Cell differentiation; Diabetes; Insulin-producing cells

Mesh:

Substances:

Year:  2015        PMID: 25724395     DOI: 10.1016/j.gene.2015.02.061

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  3 in total

1.  In vitro preconditioning of insulin-producing cells with growth factors improves their survival and ability to release insulin.

Authors:  Muhammad Sohail Anjum; Azra Mehmood; Faiza Mahmood; Muhammad Ali; Moazzam Nazir Tarrar; Shaheen N Khan; Sheikh Riazuddin
Journal:  J Biosci       Date:  2018-09       Impact factor: 1.826

Review 2.  β-Cell Replacement Strategies: The Increasing Need for a "β-Cell Dogma".

Authors:  Andhira Vieira; Noémie Druelle; Fabio Avolio; Tiziana Napolitano; Sergi Navarro-Sanz; Serena Silvano; Patrick Collombat
Journal:  Front Genet       Date:  2017-06-06       Impact factor: 4.599

3.  Therapeutic efficacy of differentiated versus undifferentiated mesenchymal stem cells in experimental type I diabetes in rat.

Authors:  M A Wassef; H Fouad; D Sabry; N Afifi; A M Abbas; W Mostafa; S H Ahmed
Journal:  Biochem Biophys Rep       Date:  2016-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.